AbbVie and Swiss drug giant Roche Holding are jointly developing venetoclax, which is sold under the brand names Venclexta and Venclyxto and approved for indications in chronic lymphocytic leukemia and acute myeloid leukemia.

Source: https://www.marketscreener.com/quote/stock/ABBVIE-INC-12136589/news/AbbVie-Phase-3-Venetoclax-Dexamethasone-Study-Falls-Short-in-Multiple-Myeloma-44952641/?utm_medium=RSS&utm_content=20230929

However, two healthcare names stand out, Roche Holding AG (); this is hardly a coincidence as Swiss bellwethers tend to trade at comparatively expensive levels, which is illustrated by the iShares MSCI Switzerland ETF's () P/E of 22.97x.

Source: https://seekingalpha.com/article/4637005-ivlu-ex-us-value-stocks-buy-if-not-fx-risks?source=feed_all_articles